Intercept to Report First Quarter 2016 Financial Results on May 5
Get Alerts ICPT Hot Sheet
Join SI Premium – FREE
NEW YORK, April 28, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals Inc. (Nasdaq: ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that it will report first quarter 2016 financial results after the NASDAQ Market closes on Thursday, May 5, 2016. Intercept management will conduct a conference call and webcast on Thursday, May 5, 2016 at 5:00 p.m. ET to discuss these results.
Dial-in and webcast information will be available on the Investors page of Intercept’s website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept’s website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases. The Company's lead product candidate, obeticholic acid (OCA), is a novel farnesoid X receptor (FXR) agonist. OCA is being developed to treat a variety of chronic liver diseases, including primary biliary cirrhosis, recently renamed primary biliary cholangitis (PBC), non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and biliary atresia (BA). The FDA has granted OCA breakthrough therapy designation for the treatment of NASH with liver fibrosis and granted OCA fast track designation for the treatment of patients with PBC. OCA has also received orphan drug designation in both the United States and Europe for the treatment of PBC and PSC. Intercept owns worldwide rights to OCA outside of Japan, China and Korea, where it has out-licensed the product candidate to Sumitomo Dainippon Pharma. Intercept's pipeline of product candidates includes other novel bile acid analogs such as INT-767, which is in clinical development. For more information about Intercept, please visit the Company's website at:www.interceptpharma.com.
Contact For more information about Intercept Pharmaceuticals, please contact: Mark Vignola +1-646-747-1000 [email protected] Christopher Frates +1-646-757-2371 [email protected]Source: Intercept Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Artisan Partners Asset Management Inc. Reports 1Q24 Results
- Oregon Pacific Bancorp Announces First Quarter 2024 Earnings Results
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!